News / Africa

Africa Urged to Increase Monitoring of Drug Trials

New drugs must be tested before they can be sold. Ethical testing requires what’s called 'informed consent,' which means the participants must not only agree to take part but also have a real understanding of the procedure. But some of those tests, or clinical trials, have come under criticism. Some pharmaceutical companies have been accused of exploiting the test subjects, who may not understand how the process works.

A number of international documents set ethical standards for drug trials, including the World Medical Association’s Declaration of Helsinki and the WHO’s Good Clinical Practice Guidelines. They stipulate that medical experiments with human subjects must uphold the highest respect for the rights and welfare of study participants.

Some drug companies say they do meet ethical standards. For instance, the U.S.-based Pfizer company has its own guidelines. They include allowing independent ethics institutions to validate the process before the trials begin and obtaining informed consent from trial subjects. They also call for limiting risks as much as possible and guaranteeing healthcare for participants who emerge with complications.

Problems

But the international guidelines and strong ethical frameworks are not mandatory.

Critics point to controversies that they say involved wealthy Western drug companies and poorly informed subjects. An official in Cameroon’s Ministry of Health who wished to remain anonymous said researchers testing new drugs in the country have sidestepped both national and international guidelines.

Health care activists want to be sure all participants understand what's involved in a drug trial
Health care activists want to be sure all participants understand what's involved in a drug trial

One case in 2005, an antiviral AIDS medication, made headlines around the world, and other clinical trials have led to abuses as well.

In that case, ethics violations in Cameroon put an end to clinical trials for tenofovir, an antiviral AIDS medication that was being developed by the U.S. pharmaceutical company Gilead Sciences. Among other complaints, French-speaking trial subjects were given questionnaires written in English. Critics say the company was using Cameroonians as guinea pigs for profit-making.

Reasons for Testing

Until about 1995, most clinical trials were conducted in Europe, the United States and Japan. Today experts estimate that more than 100,000 trials are conducted in different countries every year, with 10 percent of them in the developing world and one percent in Africa.

There are several reasons why drug companies are relocating clinical trials.

Some researchers note that to obtain valid and timely results from HIV trials, the companies must test people in areas with high rates of infection. They also say the genetic variability of HIV requires that candidate vaccines be tested in different areas of the world where different strains are present.

Dr. Mona Khanna of  the University of Illinois College of Medicine, says for the drug companies, there’s also a large number of willing participants.

"I think the reason so many clinical trials are being done in Africa is because they have a lot of people," said Khanna. That’s the first thing. So you can find many men, women and children, whatever you need, very quickly. They also have low cost. In other words, for companies to conduct trials in the US there’s a lot of cost associated with it, whereas in Africa, you go and set up a clinic; it’s much less cost."

Sonia Shah, author of the book Body Hunters, says many subjects are not aware of the procedure, or their rights, thus reducing the risk of expensive litigation.

Critics say many subjects also do not understand the rules of the trials: literacy rates are low, written agreements are misunderstood and many come from cultures that accept authority without question. In some cases, subjects are pressured into the trials by local committees, some which may receive pay from the companies. They may also feel they can not quit a clinical trial because they or their children would lose out on good health care or treatment.

Calls for change

One of those advocating change is Professor Ames Dhai, director of the Steve Biko Center for Bioethics in Johannesburg and a lecturer at Witswatersrand University. She says Africa must stop blaming the West and assume responsibility for monitoring the trials.

"I think we need to blame ourselves if nothing is changing," said Dhai, "and I think it’s time we stopped blaming the West and started looking at ourselves and how we can approach the issue. We all spend a lot of time looking at informed consent, regulatory and administrative issues. But we don’t spend enough time looking at justice in terms of what’s going to happen after the trials – have our populations been exploited in the process of research?"

Dhai mentions poor governance, corruption, conflicts, illiteracy and lack of knowledge about drugs as factors contributing to the inability of many African countries to review the proposals and monitor the trials.

Dr.  Mona Khanna of the University of Illinois says African countries must set up effective ethics committees and establish sanctions.

"If there are no penalties associated with enforcement," she said, "people will do whatever they want to do. If the local authorities or regulatory bodies find companies that are doing ABC or D, you have to fine them or tell them [they] can never come back."

Author Sonya Shah says African leaders should introduce legislation requiring drug trial funders to contribute to local scientific research with medical equipment and programs that would benefit communities.

Others say because the US Food and Drug Administration lacks the resources to monitor overseas trials, countries should form their own ethics committees to ensure drug testing benefits the communities involved.

They also say some procedures could be changed.

Today, many test a new drug against a placebo, a treatment known to be ineffective. That’s cheaper for the companies, but patients taking placebos are not receiving any treatment. Critics say a better idea would be to replace a placebo – when possible -- with an older or less effective drug. At least that way, they say all of the subjects will get some type of treatment that may benefit them.

But even critics like Professor Khanna agree that the trials, when scrutinized more effectively, can help advance the fight against HIV, malaria and other diseases on the continent.

Today Africa is one of the biggest beneficiaries of free and discounted medicines from the West. The Global Fund for the Fight against HIV/AIDS, Malaria and TB, and the U.S.-backed President’s Emergency Plan for AIDS Relief (PEPFAR) are among several programs working to ensure that Africans get medication at affordable rates.

You May Like

Video VOA Reporter Tours Devastated Peshawar School

Islamist militants wearing military uniforms and strapped with explosives attacked a military run school Tuesday in the northwestern Pakistani city of Peshawar. At least 141 people were killed in the horrific attack, most of them young students. More

Video Sudan School Becomes Target of Aerial Attacks

Dropout rate at an all-time high in South Kordofan state because many schools have been destroyed during 3-year civil war More

Tennessee Songbirds Fly Coop Long Before Tornadoes Arrive

Researchers say birds apparently alerted to danger by sounds at frequencies below range of human hearing More

This forum has been closed.
Comments
     
There are no comments in this forum. Be first and add one

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
US: Response to Sony Hack Will Be Proportionali
X
Aru Pande
December 19, 2014 1:45 AM
The White House says President Barack Obama considers the cyberattack on Sony Corp. a serious national security matter and that the U.S. will counter with an "appropriate response." VOA correspondent Aru Pande reports.
Video

Video US: Response to Sony Hack Will Be Proportional

The White House says President Barack Obama considers the cyberattack on Sony Corp. a serious national security matter and that the U.S. will counter with an "appropriate response." VOA correspondent Aru Pande reports.
Video

Video Sudan School Becomes Target of Aerial Attacks

The school dropout rate is at an all-time high in Sudan's South Kordofan state because many schools have been destroyed during the three-year civil war between the government and SPLA-N rebel forces. Adam Bailes visited Sudan's Nuba Mountains' region and reports many children are simply too scared to go to school
Video

Video Nigerians Fleeing Boko Haram Languish in Camp Near Capital

In its five-year effort to impose Islamic law in northeastern Nigeria, the Boko Haram extremist group has killed thousands of people and forced hundreds of thousands to flee. Some of those who ran for their lives now live in squalor on the edges of the capital, Abuja. Chris Stein reports for VOA.
Video

Video Putin Says Russian Economy Will Emerge Stronger

Russian President Vladimir Putin has said his country's sinking economy will not only recover but also become stronger, despite falling oil prices and Western sanctions over Ukraine. VOA's Daniel Schearf reports.
Video

Video Detained Turkish Journalists Follow Teachings of US-Based Preacher

The Turkish government’s jailing of critical journalists has sparked international condemnation and is being seen as an effort to undermine the followers of an ailing Turkish preacher based in the United States. VOA religion reporter Jerome Socolovsky has more.
Video

Video ‘Anti-Islamization’ Marches Increase Tensions In Germany

Anti-immigrant rallies in Germany have been building in recent weeks, peaking Monday night in the city of Dresden where tens of thousands of people turned out to demonstrate against what they call the ‘Islamization’ of the West. Germany has offered asylum to more Syrian refugees than any other country, and this appears to have set off the protests. Henry Ridgwell reports from London.
Video

Video Aceh Rebuilt Decade After Tsunami, But Scars Remain

On December 26, 2004 there was an earthquake in the Indian Ocean so powerful it caused the Earth’s axis to wobble a few centimeters. Onshore on the island of Sumatra, the resulting tsunami was devastating. A decade later, VOA Correspondent Steve Herman reports from Banda Aceh, Indonesia, where although there is little remaining evidence of the physical devastation, the psychological scars among survivors remain.
Video

Video Refugees Living in Kenya Long for Peace in the Home Countries

Kenya is host to numerous refugees seeking safe haven from conflict. Immigrants from Somalia face challenges in their new lives in Kenya. Ahead of International Migrants Day (December 18) Lenny Ruvaga has more for VOA News from the Kenyan capital.

All About America

AppleAndroid